News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C news

Show

From To
New and experimental hepatitis C treatment
Simeprevir & sofosbuvir demonstrates good early cure rate with or without ribavirin

An all-oral combination of simeprevir plus sofosbuvir, with or without ribavirin, led to an early cure for most hard-to-treat prior null responders with genotype 1 hepatitis C

Published
12 March 2013
By
Liz Highleyman
Medical procedures and other blood-borne exposure
NY aims to prevent unsafe injections

The Safe Injection Practices Coalition, a group of healthcare-related organizations including the CDC indicated since 2001, more than 150,000 patients in the U.S. were told they may have been exposed to hepatitis B, hepatitis C, or human immunodeficiency virus because providers followed unsafe injection procedures.

Published
12 March 2013
From
UPI.com
Hepatitis C treatment
Telaprevir shows promise in black patients with genotype 1 HCV

Preliminary data presented here at the 2013 Conference on Retroviruses and Opportunistic Infections show that combination telaprevir treatment may be effective in black null responder patients with chronic genotype 1 hepatitis C.

Published
12 March 2013
From
Healio
New and experimental hepatitis C treatment
Faldaprevir ups interferon response in HIV/HCV co-infection

Adding the hepatitis C virus (HCV) protease inhibitor faldaprevir (formerly BI 201335) to pegylated interferon and ribavirin led to a higher early response rate and the potential

Published
11 March 2013
By
Liz Highleyman
New and experimental hepatitis C treatment
Simeprevir pushes HCV cure rate above 75% for HIV/HCV co-infection

Adding the new hepatitis C virus (HCV) protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cures about three-quarters of HIV/HCV co-infected people, most of them with

Published
11 March 2013
By
Liz Highleyman
Hepatitis C transmission and prevention
England: lack of planning for hepatitis C services risks future chaos and huge healthcare costs

New report finds that local authorities and NHS organisations need to prioritise hepatitis C now or risk missing a rare opportunity.

Published
11 March 2013
From
Hepatitis C Trust press release
Pharmaceutical industry
Pfizer stops developing hepatitis C drug

Pfizer Inc. has stopped development of an experimental hepatitis C drug, bowing out of a hotly contested industry race to introduce the next generation of treatments for the infectious liver disease.

Published
10 March 2013
From
EATG
New and experimental hepatitis C treatment
Four in Five People With HIV and Hep C on Faldaprevir Achieve Early Treatment Success

Interim results from a trial of the hep C drug faldaprevir, given to people coinfected with hep C and HIV, have shown an 80 percent early success rate.

Published
07 March 2013
From
AIDSMeds
Hepatitis C treatment
French studies report real-world data on use of telaprevir and boceprevir in people with HIV and hepatitis C co-infection

Adding boceprevir or telaprevir to interferon-based therapy showed promising indications of efficacy and acceptable safety for difficult-to-treat HIV/HCV co-infected prior non-responders in a pair of French studies presented

Published
05 March 2013
By
Liz Highleyman
Hepatitis C treatment
Patient Dilemma: Treat Hepatitis C Now or Hold Out?

Being diagnosed with a potentially fatal disease usually triggers immediate treatment. But a growing number of people infected with hepatitis C are putting off therapy, choosing instead to roll the dice and wait for a new generation of drugs to become available.

Published
05 March 2013
From
Wall Street Journal
← Prev12345...59Next →

Filter by country